Flynn Management LLC, its general partner
@Deerfield Management Company, L.p. (series C)
Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters
Portfolio positions
This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.
Assets under management
The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RVMDRevolution Medicines Inc
| 1.98% | $132.091M 2.913M shares@ $45.35 avg price | Decreased -5.74% |
ALHCAlignment Healthcare Inc
| 1.92% | $128.306M 10.855M shares@ $11.83 avg price | Decreased -0.42% |
CPRXCatalyst Pharmaceuticals Inc
| 1.86% | $123.845M 6.23M shares@ $19.89 avg price | Decreased -31.74% |
AHCOAdapthealth Corp
| 1.63% | $109.059M 9.711M shares@ $11.23 avg price | Decreased -26.75% |
OMIOwens & Minor Inc New
| 1.16% | $77.069M 4.912M shares@ $15.7 avg price | Decreased -22.9% |
SGRYSurgery Partners Inc
| 0.86% | $57.396M 1.78M shares@ $32.25 avg price | Decreased -62.18% |
CVSCvs Health Corp
| 0.83% | $55.007M 874,800 shares@ $62.88 avg price | Decreased -10.27% |
CGEMCullinan Therapeutics Inc
| 0.83% | $54.907M 3.28M shares@ $16.74 avg price | Decreased 0% |
BIOBio Rad Labs Inc
| 0.76% | $50.714M 151,575 shares@ $334.59 avg price | Decreased -0.09% |
EWTXEdgewise Therapeutics Inc
| 0.72% | $47.535M 1.781M shares@ $26.69 avg price | Decreased -38.04% |